BioNTech

Develops personalized immunotherapies with a focus on cancer medicine.

Launch date

2008

Employees

1001-5000 people

Market cap

Net debt

-

Enterprise valuation

$5.5b (Public information from May 2024)

Company register number HRB 48720 (Mainz)

Mainz Rhineland-Palatinate (HQ)

https://www.biontech.com/

https://twitter.com/biontech_group https://www.linkedin.com/company/biontech-se/